Biodyne has contributed to the early diagnosis of cancer through screening enhancement. We continuously research and develop so as to improve the efficiency of our unique technology for a liquid-based cytology system for cancer diagnosis.
We have developed and obtained a patent for a liquid-based cytology system designed to be a fully-automated cancer diagnosis process. Specific reagents were created in 2005 and 2006. Biodyne is renowned as the first company in Korea to develop and obtain a patent for this system and still remains as the sole supplier of automatic equipment in Korea. The reagents for cancer diagnosis are also manufactured with patent technology in a fully automated sanitized facility that meets government regulations.
Biodyne's representative products, Cellprep-a Liquid-Based Cytology system and the accompanying reagents have already proved to be of outstanding quality when compared to other well-known imported equipment within the global medical market. This has been made possible through on-going proactive research by prominent doctors and scholars both in Korea and abroad. Our products are the result of our dedicated efforts in realizing both a productive and economic efficient culture within Biodyne. At Biodyne, professionals are putting their talent and potential together so as to create products that far exceed the requirements of customers. The motivation that drives our professionals to constantly strive to develop better reagents for enhanced cell smear and preservation is to keep a promise. This promise is that we will strive to be the best at realizing a healthier world while endeavouring to be a moral standard that will guide others in the field. Such a goal cannot be reached by simply pursuing profits alone.